Home / Letter From The Editor / July 24, 2021

July 24, 2021

Jul 24, 2021
 

The number of GLP1-RA’s has grown over the past few years, and the fact that there are still new ones working their way towards approval can be viewed as a measuring stick to how important this class will be for treating diabetes now and going forward. Each time a new class member comes out, the manufacturer is forced to find a way to differentiate itself from the rest of the class. This could be as simple as a better delivery device, or looking for new benefits in patient care. This week our intern Alan Martinez, PharmD Candidate, USF College of Pharmacy, takes a look at Efpeglenatide, the newest GLP1-RA, and the unique benefits for cardiovascular and renal protection, in our Laterpay feature.

 

*****************************

 

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief